

SO820, "A Double Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients with Stage O-III Colon or Rectal Cancer, Phase III – Preventing Adenomas of the Colon with Eflornithine and Sulindac (PACES)"

August 2017

PACES/S0820 News

Accrual Update

As of July 31, 2017: 156 patients are registered, averaging 6 patients per month over the past 8 months.

Keep it up! Help reach these goals:

- 8 patients per month
- study goal of 480 patients

Congratulations to these sites that have registered 5 or more patients to the trial!

Kaiser Permanente NCORP (Harbor City)

UC Irvine Medical Center

University of Texas San Antonio, Cancer Therapy & Research Center

Wichita NCORP (Cancer Center of Kansas-Wichita)
Yale University

Retention and Adherence Tips

Adherence starts once a patient is enrolled in the study. Challenges to drug and follow-up adherence are often temporary and can be resolved if addressed early. Consider strategies to address common retention and adherence challenges (protocol section 7.6, Adherence/Compliance).

- Look for adherence warning signs
 (missing clinic visits, patient comments about study drugs, illness, etc.)

 See Warning Signs of Poor Adherence:
 https://swog.org/Visitors/S0820/Warningsigns.pdf.
- Check in periodically with the patient to identify potential barriers and offer suggestions to address challenges. Refer to Promoting Adherence Strategies for ideas: https://swog.org/Visitors/S0820/Warningsigns.pdf.

NSAIDs and Patient Eligibility

Question: Can a patient take nonsteroidal anti-inflammatory drugs (NSAIDs) and still be

eligible to participate in the study?

Answer: Yes, patients are eligible under the following circumstances:

Nonsteroidal anti-inflammatory drugs (NSAIDs) like ibuprofen, Advil®, Motrin®, Aleve®, Ketoprofen, or Orudis® may not be taken more frequently than 10 days per month. Aspirin may be taken as long as the dose is 100 mg or less per day or two 325 mg tablets or less per week. See protocol section 5.2b.10 (Clinical/Laboratory Criteria).

SWOG Study Co-Coordinators: Jason A. Zell, DO, MPH Powel Brown M.D. PhD

NRG Study Co-Coordinator: Jennifer Dorth, MD

ECOG-ACRIN Study Co-Coordinator: Raymond Bergan, MD

Alliance Study Co-Coordinator: Nancy You, MD

Questions? Contact <u>CancerControlQuestion@crab.org</u>